ISB Gets $6.5 Million from NCI
News Oct 14, 2014
Institute for Systems Biology (ISB) has received a $6.5 million two-year contract from the NIH’s National Cancer Institute (NCI) to develop a cloud-based platform that will serve as a large-scale data repository and provide the computational infrastructure necessary to carry out cancer genomics research at unprecedented scales.
ISB’s Shmulevich group will serve as the lead on the project with two partners: Google, Inc., and SRA International, Inc. (a Fairfax, Va.-based provider of IT solutions and professional services to government organizations).
Called the Cancer Genomics Cloud (CGC), the project will migrate the massive amounts of data collected from TCGA (The Cancer Genome Atlas) to Google Cloud Platform and, importantly, provide easy and secure access to that information, with the requisite compute power to manage and analyze large datasets.
Funded by the NCI and the National Human Genome Research Institute, TCGA is a comprehensive and coordinated effort to accelerate understanding of the molecular basis of cancer through the application of genome analysis technologies, including large-scale genome sequencing.
“The CGC will democratize access to the wealth of cancer genomics data by substantially lowering the barrier to accessing and computing over these datasets,” said Dr. Ilya Shmulevich, professor at ISB and CGC prime investigator. “Cancer researchers will be able to analyze and explore entire cohorts of rich genomic data, without needing access to a large local compute cluster. The CGC will also facilitate collaborative research by allowing scientists to work on common datasets and projects in a cloud environment.”
ISB, which houses one of the Genome Data Analysis Centers within the TCGA project, will respond to the needs of the research community and spearhead the development of applications that will provide community access to the cloud-based data and computational infrastructure. ISB will also provide programmatic examples for others in the research community to develop novel methods and applications.
Existing 20-year-old Multiple Sclerosis Drug Effective Against Multi-resistant BacteriaNews
A widely-used and twenty-year-old medicine used to treat multiple sclerosis can also beat a type of multi-resistant bacteria for which there are currently only a few effective drugs.READ MORE
Advanced Prostate Cancer: EMA Approves Abiraterone Combined With Hormone Therapy as First-line TreatmentNews
The prostate cancer drug abiraterone has been approved by the European Medicines Agency in combination with standard hormone therapy for use as a first-line treatment for advanced prostate cancer.READ MORE
Cancer Cells Prevent Immune Cells from Producing Cancer Killing ChemicalsNews
Researchers have identified a substance released by pancreatic cancer cells that protects them from attack by immune cells called macrophagesREAD MORE
Comments | 0 ADD COMMENT
3rd Annual NGS Data Analysis and Informatics Conference
Feb 08 - Feb 09, 2018
3rd Annual Genome Editing & Engineering Conference
Feb 08 - Feb 09, 2018